71 West Capital Partners Makes New Investment in Abbott Laboratories $ABT

71 West Capital Partners purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,929 shares of the healthcare product maker’s stock, valued at approximately $993,000.

Other large investors have also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $26,000. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $27,000. Finally, Intesa Sanpaolo Wealth Management purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $29,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently commented on ABT. BTIG Research reaffirmed a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a research note on Monday, April 27th. JPMorgan Chase & Co. decreased their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Stifel Nicolaus decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Evercore decreased their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $118.38.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $88.76 on Tuesday. The stock has a market cap of $154.60 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The firm’s fifty day simple moving average is $91.17 and its 200 day simple moving average is $107.56. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the business posted $1.09 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.